Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
Saxenda helps patients feel satisfied with smaller meals, reduces the desire to graze between eating periods, and improves control over cravings
Glutathione is sometimes associated with hormonal processes, but it is not the same as a hormone
"One of the things that I realized the very first time I took a GLP-1 was that all these years I thought that thin people just had more willpower, they ate better foods, they were able to stick to it longer, they never had a potato chip, and then I realized the very first time I took the GLP-1 that, 'Oh, they're not even thinking about it
Abstract Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk